{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:48:30Z","timestamp":1786492110381,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104476"],"award-info":[{"award-number":["82104476"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110543","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T15:06:41Z","timestamp":1688396801000},"page":"110543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"122","author":[{"given":"Yamin","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-3875","authenticated-orcid":false,"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.intimp.2023.110543_b0005","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Longo","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110543_b0010","doi-asserted-by":"crossref","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"10126","key":"10.1016\/j.intimp.2023.110543_b0015","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.intimp.2023.110543_b0020","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/cac2.12110","article-title":"Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"40","author":"Hou","year":"2020","journal-title":"Cancer Commun. (London, England)"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2023.110543_b0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000487635","article-title":"Survival of hepatocellular carcinoma patients treated with sorafenib beyond progression","volume":"5","author":"Apostolidis","year":"2018","journal-title":"Gastrointestinal tumors"},{"issue":"1","key":"10.1016\/j.intimp.2023.110543_b0030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.28881","article-title":"Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: an analysis of the SEER-Medicare database","volume":"65","author":"Parikh","year":"2017","journal-title":"Hepatol. (Baltimore, MD)"},{"issue":"1","key":"10.1016\/j.intimp.2023.110543_b0035","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1186\/s12913-022-08661-4","article-title":"Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Health Serv. Res."},{"issue":"9","key":"10.1016\/j.intimp.2023.110543_b0040","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.22.00972","article-title":"Nivolumab plus Cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the checkmate 040 Trial","volume":"41","author":"Yau","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2023.110543_b0045","doi-asserted-by":"crossref","first-page":"e005457","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","volume":"10","author":"de la Torre-Al\u00e1ez","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"10088","key":"10.1016\/j.intimp.2023.110543_b0050","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.intimp.2023.110543_b0055","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib. Accessed January 13, 2023."},{"issue":"20","key":"10.1016\/j.intimp.2023.110543_b0060","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110543_b0065","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Management of Immunotherapy-Related Toxicities (version 2. 2023). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed June 3, 2023."},{"issue":"1","key":"10.1016\/j.intimp.2023.110543_b0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.110543_b0075","unstructured":"National Comprehensive Cancer Network. Hepatocellular carcinoma (version 1. 2023). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf. Accessed March 30, 2023."},{"issue":"4","key":"10.1016\/j.intimp.2023.110543_b0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Medical decision making : an Int. J. Soc. Med. Decision Making"},{"key":"10.1016\/j.intimp.2023.110543_b0085","doi-asserted-by":"crossref","first-page":"1092385","DOI":"10.3389\/fimmu.2023.1092385","article-title":"Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110543_b0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clinthera.2022.01.011","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"44","author":"Husereau","year":"2022","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2023.110543_b0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.intimp.2023.110543_b0100","unstructured":"State Administration of Foreign Exchange. Available at: http:\/\/www.safe.gov.cn\/en\/. Accessed March 30, 2023."},{"key":"10.1016\/j.intimp.2023.110543_b0105","unstructured":"Chinese drug price of drug centralized bid procurement. Available at: https:\/\/db.yaozh.com\/yaopinzhongbiao. Accessed March 30, 2023."},{"key":"10.1016\/j.intimp.2023.110543_b0110","unstructured":"Chinese Society of Clinical Oncology. CSCO guidelines in diagnosis and treatment of hepatocellular carcinoma (2022). Available at: http:\/\/www.csco.ac.cn\/ (Accessed March 30, 2023)."},{"key":"10.1016\/j.intimp.2023.110543_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in china","volume":"24","author":"Yue","year":"2021","journal-title":"Value in health regional issues"},{"key":"10.1016\/j.intimp.2023.110543_b0120","unstructured":"National Bureau of Statistics of China. Available at: http:\/\/www.stats.gov.cn\/english\/. Accessed March 30, 2023."},{"issue":"5","key":"10.1016\/j.intimp.2023.110543_b0125","doi-asserted-by":"crossref","first-page":"100702","DOI":"10.1016\/j.jhepr.2023.100702","article-title":"Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials","volume":"5","author":"Fulgenzi","year":"2023","journal-title":"JHEP reports : innovation in hepatology"},{"issue":"6","key":"10.1016\/j.intimp.2023.110543_b0130","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer immunol. Immunother. : CII"},{"issue":"4","key":"10.1016\/j.intimp.2023.110543_b0135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/17474124.2022.2064273","article-title":"Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?","volume":"16","author":"Rizzo","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110543_b0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543784.2022.2009455","article-title":"Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials","volume":"31","author":"Di Federico","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"32","key":"10.1016\/j.intimp.2023.110543_b0145","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.2217\/fon-2020-0669","article-title":"Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing","volume":"16","author":"Rizzo","year":"2020","journal-title":"Future oncology (London, England)"},{"key":"10.1016\/j.intimp.2023.110543_b0150","article-title":"Nivolumab Versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: a cost-effectiveness analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110543_b0155","first-page":"1097","article-title":"Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United states","volume":"41","author":"Wen","year":"2021","journal-title":"Liver Int. official J. Int. Association for the Study of the Liver"},{"key":"10.1016\/j.intimp.2023.110543_b0160","doi-asserted-by":"crossref","unstructured":"Sun KX, Cao SS, Shi FH, Guan Y, Tang M, Zhao MN, Jian YF, Cui B, Li ZY, Wang JW, Yu F, Ding Y. First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therapeutic advances in gastroenterology 2022, 15: 17562848221140662.","DOI":"10.1177\/17562848221140662"},{"key":"10.1016\/j.intimp.2023.110543_b0165","article-title":"Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in china: an economic evaluation based on network meta-analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.intimp.2023.110543_b0170","volume":"10","author":"Lin","year":"2022","journal-title":"Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. Frontiers in public health"},{"issue":"12","key":"10.1016\/j.intimp.2023.110543_b0175","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.dld.2016.07.007","article-title":"FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: a cost-effectiveness analysis","volume":"48","author":"Zhang","year":"2016","journal-title":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"key":"10.1016\/j.intimp.2023.110543_b0180","article-title":"Cost-effectiveness analysis of hepatic arterial infusion of FOLFOX Combined sorafenib for advanced hepatocellular carcinoma with portal vein invasion","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110543_b0185","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.3747\/co.23.2244","article-title":"Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada","volume":"23","author":"Amdahl","year":"2016","journal-title":"Current oncol. (Toronto, Ont)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:14:10Z","timestamp":1736432050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923008664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"alternative-id":["S1567576923008664"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110543","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110543"}}